Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations
- Resource Type
- Article
- Source
- In
European Journal of Cancer May 2023 184:172-178 - Subject
- Language
- ISSN
- 0959-8049